|

HPV Genotype Attribution and Disease Burden of Anal Cancer in China

RECRUITINGSponsored by Fudan University
Actively Recruiting
SponsorFudan University
Started2025-06-01
Est. completion2027-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06670495

Summary

To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* (1) Patients diagnosed with anal cancers, (2) Patients without radiation or chemotherapy prior to specimen collection;

Exclusion Criteria:

* (1) Patients with HIV infection, (2) Patients with immunosuppression after solid organ transplantation, (3) Those who do not agree to specimen collection and testing, (4) For retrospective study cases, those who without specimen.

Conditions2

Anal CancerCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.